ARS Pharmaceuticals, Inc. — Director's Dealing 2024

Oct 10, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2024-10-08

Reporting Person: Tanimoto Sarina (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-10-08	Common Stock	S	50000	$13.8277	Disposed	1346494	Indirect
2024-10-08	Common Stock	S	50000	$13.8278	Disposed	1348499	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	3407847	Direct
Common Stock	1447447	Indirect
Common Stock	4315313	Indirect

Footnotes

F1: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.

F2: The weighted average sale price for the transaction reported was $13.8277, and the range of prices were between $13.60 and $14.025. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F3: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

F4: The weighted average sale price for the transaction reported was $13.8278, and the range of prices were between $13.60 and $14.035. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F5: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust.

F6: The Reporting Person is trustee of the trust.